KalVista Pharmaceuticals, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Audhya Paul K. | CHIEF MEDICAL OFFICER | Option Exercise | 5,000 | — | — | 85,880 | Aug 23, 2024 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | Option Exercise | 3,125 | — | — | 87,592 | Aug 23, 2024 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | Sale | 7,973 | $12.01 | $95,756 | 80,880 | Aug 17, 2024 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sale | 14,215 | $12.01 | $170,722 | 242,527 | Aug 17, 2024 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sale | 7,102 | $12.01 | $85,295 | 84,467 | Aug 17, 2024 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sale | 7,465 | $11.53 | $86,071 | 224,547 | Jun 6, 2024 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Option Exercise | 51,031 | — | — | 238,346 | May 20, 2024 |
| Feener Edward P. | CHIEF SCIENTIFIC OFFICER | Sale | 8,088 | $11.76 | $95,115 | 72,858 | May 17, 2024 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | Sale | 13,175 | $11.76 | $154,938 | 70,325 | May 17, 2024 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sale | 11,610 | $11.76 | $136,534 | 80,074 | May 17, 2024 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | Option Exercise | 30,613 | — | — | 67,181 | Feb 20, 2024 |
| Crockett Thomas Andrew | CEO | Option Exercise | 54,415 | — | — | 236,091 | Feb 20, 2024 |
| Feener Edward P. | CHIEF SCIENTIFIC OFFICER | Sale | 8,397 | $14.11 | $118,482 | 82,048 | Feb 17, 2024 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sale | 12,053 | $14.11 | $170,068 | 72,895 | Feb 17, 2024 |
| Palleiko Benjamin L | CFO, CBO | Sale | 22,802 | $14.11 | $321,736 | 187,315 | Feb 17, 2024 |
| Palleiko Benjamin L | CFO, CBO | Sale | 40,855 | $15.01 | $613,234 | 159,088 | Feb 14, 2024 |
| Crockett Thomas Andrew | CEO | Sale | 58,356 | $15.01 | $875,924 | 181,676 | Feb 14, 2024 |
| Feener Edward P. | CHIEF SCIENTIFIC OFFICER | Sale | 28,171 | $15.01 | $422,847 | 71,657 | Feb 14, 2024 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sale | 39,886 | $15.01 | $598,689 | 66,160 | Feb 14, 2024 |
| Palleiko Benjamin L | CFO, CBO | Award / Grant | 87,500 | — | — | 199,943 | Feb 11, 2024 |
| Feener Edward P. | CHIEF SCIENTIFIC OFFICER | Award / Grant | 60,000 | — | — | 99,828 | Feb 11, 2024 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | Award / Grant | 60,000 | — | — | 106,046 | Feb 11, 2024 |
| Crockett Thomas Andrew | CEO | Award / Grant | 122,500 | — | — | 240,032 | Feb 11, 2024 |
| Shah Nimish P | — | Purchase | 51,827 | $14.56 | $754,601 | 4,794,984 | Feb 8, 2024 |
| Crockett Thomas Andrew | CEO | Sale | 700 | $16.81 | $11,767 | 117,532 | Feb 1, 2024 |
| Venrock Healthcare Capital Partners III, L.P. | — | Purchase | 88,099 | $14.47 | $1,274,793 | 4,738,683 | Jan 30, 2024 |
| Venrock Healthcare Capital Partners III, L.P. | — | Purchase | 80,600 | $14.22 | $1,146,132 | 4,650,584 | Jan 26, 2024 |
| VHCP Management EG, LLC | — | Purchase | 10,897 | $12.54 | $136,648 | 4,538,094 | Jan 22, 2024 |
| VHCP Co-Investment Holdings III, LLC | — | Purchase | 39,680 | $12.51 | $496,397 | 4,434,651 | Jan 19, 2024 |
| Koh Bong Y | — | Purchase | 6,647 | $12.68 | $84,284 | 4,296,447 | Jan 16, 2024 |
| Feener Edward P. | Chief Scientific Officer | Sale | 22,679 | $13.03 | $295,507 | 39,828 | Jan 11, 2024 |
| Venrock Healthcare Capital Partners III, L.P. | — | Purchase | 20,816 | $12.56 | $261,449 | 4,242,100 | Jan 8, 2024 |
| Feener Edward P. | Chief Scientific Officer | Sale | 100 | $13.00 | $1,300 | 62,507 | Jan 8, 2024 |
| Shah Nimish P | — | Purchase | 17,605 | $12.20 | $214,781 | 4,110,336 | Jan 4, 2024 |
| Koh Bong Y | — | Purchase | 41,514 | $11.97 | $496,923 | 3,615,228 | Dec 28, 2023 |
| Crockett Thomas Andrew | CEO | Sale | 30,000 | $12.02 | $360,600 | 127,532 | Dec 27, 2023 |
| Audhya Paul K. | Chief Medical Officer | Option Exercise | 18,530 | — | — | 44,553 | Nov 20, 2023 |
| Palleiko Benjamin L | President, CFO, CBO & Sec'y | Option Exercise | 30,197 | — | — | 125,451 | Nov 20, 2023 |
| Feener Edward P. | Chief Scientific Officer | Sale | 4,958 | $8.23 | $40,804 | 79,828 | Nov 17, 2023 |
| Yea Christopher | Chief Development Officer | Sale | 7,113 | $8.23 | $58,540 | 46,046 | Nov 17, 2023 |
| Crockett Thomas Andrew | CEO | Sale | 14,807 | $8.23 | $121,862 | 157,532 | Nov 17, 2023 |
| Crockett Thomas Andrew | CEO | Gift | 8,000 | — | — | 138,756 | Oct 30, 2023 |
| Cha Albert | — | Option Exercise | 12,000 | $7.88 | $94,560 | 18,000 | Sep 11, 2023 |
| Yea Christopher | Chief Development Officer | Option Exercise | 11,494 | — | — | 48,804 | Aug 18, 2023 |
| Palleiko Benjamin L | President, CFO, CBO & Sec'y | Option Exercise | 30,195 | — | — | 108,321 | Aug 18, 2023 |
| Audhya Paul K. | Chief Medical Officer | Sale | 8,020 | $10.73 | $86,055 | 26,023 | Aug 17, 2023 |
| Feener Edward P. | Chief Scientific Officer | Sale | 4,976 | $10.73 | $53,392 | 73,289 | Aug 17, 2023 |
| Crockett Thomas Andrew | CEO | Sale | 14,876 | $10.73 | $159,619 | 146,756 | Aug 17, 2023 |
| Palleiko Benjamin L | President, CFO, CBO & Sec'y | Option Exercise | 9,364 | — | — | 82,163 | May 18, 2023 |
| Feener Edward P. | Chief Scientific Officer | Option Exercise | 4,205 | — | — | 68,557 | May 18, 2023 |